{"filing":{"accession_number":"0001104659-26-073559","cik":"0001583107","ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tm2617876d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926073559/tm2617876d1_8k.htm"},"events":[{"id":10335,"run_id":9064,"accession_number":"0001104659-26-073559","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from the 2026 Annual General Meeting held on June 12, 2026, covering three proposals: election of six directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches Item 5.07 requirements and presents tabulated voting outcomes for each matter.","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6627,"accession_number":"0001104659-26-073559","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the 2026 Annual General Meeting held on June 12, 2026, covering three proposals: election of six directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches Item 5.07 requirements and presents tabulated voting outcomes for each matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:49.054122+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6627,"accession_number":"0001104659-26-073559","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from the 2026 Annual General Meeting held on June 12, 2026, covering three proposals: election of six directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. The filing directly matches Item 5.07 requirements and presents tabulated voting outcomes for each matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:49.054122+00:00","company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","filing_date":"2026-06-12"}]}